AbbVie to acquire ImmunoGen for $10.1bn to expand oncology portfolio

AbbVie Inc. and ImmunoGen Inc. have entered into a definitive agreement, marking a significant move in the pharmaceutical industry. AbbVie will acquire ImmunoGen, including its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx), for $31.26 per share in cash, totaling an equity value of approximately $10.1 billion.

ELAHERE: A Breakthrough in Cancer Treatment

The acquisition is a strategic step for AbbVie, as it strengthens its commercial and clinical presence in the solid tumor space. ELAHERE, a first-in-class antibody-drug conjugate approved for platinum-resistant ovarian cancer, adds a key asset to AbbVie’s oncology portfolio.

Commitment to Diversifying Oncology Pipeline

Richard A. Gonzalez, Chairman and CEO of AbbVie, highlighted the acquisition’s alignment with the company’s long-term growth strategy. The merger aims to diversify AbbVie’s oncology pipeline, covering both solid tumors and hematologic malignancies.

AbbVie acquisition of ImmunoGen. Photo courtesy of AbbVie Inc.

ImmunoGen’s Vision and Potential

Mark Enyedy, President and CEO of ImmunoGen, expressed confidence in AbbVie’s ability to expand ELAHERE’s reach. The addition of ImmunoGen’s pipeline, platform, and expertise promises to advance innovation in antibody-drug conjugates (ADCs).

ELAHERE’s Market Potential and Clinical Progress

ELAHERE, targeting folate receptor alpha with a maytansinoid payload, received FDA accelerated approval in 2022. The positive results from the Phase 3 MIRASOL trial will support further applications for marketing authorization in the European Union and a supplemental submission to the U.S. FDA.

ImmunoGen’s Pipeline Expansion under AbbVie

AbbVie’s acquisition expands its oncology pipeline with ImmunoGen’s next-generation ADCs. These include IMGN-151, a potential treatment for ovarian cancer and other solid tumors, and Pivekimab sunirine, targeting a rare blood cancer.

Transaction Terms and Expected Outcomes

The transaction, expected to close in mid-2024, is subject to ImmunoGen shareholder and regulatory approvals. AbbVie anticipates the acquisition to be accretive to diluted earnings per share beginning in 2027, signifying a major impact on the pharmaceutical sector.